Introduction {#sec1-1}
============

Osteoid osteoma (OO) is a small, benign, osteoblastic lesion that appears primarily in young patients ([@ref1]-[@ref3]). Even though OO is a benign lesion, surgical treatment may be necessary if pain is persistent.

In the past, open "en bloc" surgical excision has been considered the gold standard for treatment of OO with an overall success of 88% ([@ref4]-[@ref6]). Disadvantages of open surgical procedure include a large bone and soft tissue damage ([@ref3]). Furthermore, wider resection of the lesion may cause a bone defect that becomes a zone of lower mechanical resistance which, if subjected to stresses early, may create a fracture ([@ref7]).

In the last two decades, percutaneous CT-guided procedures have been developed for the treatment of OO's. Some authors reported percutaneous drill resection with a success rate similar to the open techniques, from 84% to 100% ([@ref8]-[@ref10]). However, this technique is associated with a high number of complications, up to 24%, represented mainly by fractures and infections ([@ref7]).

Currently, radiofrequency ablation (RFA) is the gold standard in the treatment of OO with high success and low complication rates. The active electrode needle tip is able to induce thermal coagulative necrosis of the lesion through a controlled increase of the temperature ([@ref11]-[@ref13]).

Recurrence rate of the lesion, after open or percutaneous surgery, is related to the presence of residual areas of nidus. In RFA, the main risk factor for recurrence is the non-optimal positioning of the electrode needle and larger OO's. In lesions greater than 10 mm reposition of the electrode needle and multiple ablations are recommended to reduce the risk of recurrence ([@ref14]-[@ref16]).

The need to induce thermal ablation in a wider area, especially in lesions larger than 10 mm, led us to use a multi-tined expandable electrode system (MTEES). It consists of a central straight-needle cannula that is used to deploy an array of curved electrode tines from the tip to the adjacent tissue, which allows a wider coagulative necrosis of the lesion.

Objective {#sec1-2}
=========

The aim of this retrospective study is to examine the efficacy and safety of RFA using a MTEES in patients with symptomatic OO.

Methods {#sec1-3}
=======

Between January 2005 and June 2007, 16 patients (10M, 6F) with symptomatic OO's were treated by CT-guided percutaneous RFA using a MTEES. The average age at surgery was 19 ± 3.3 years (range 14--26 years). We detected 10 lesions in the femur (62.5%) and 6 (37.5%) in the tibia. The side mostly affected was the left (10 cases). The mean duration of pain before the procedure was 12.5 ± 5.3 months (range 6--24 months). Medical records of patients were analyzed retrospectively after ethics committee approval. No histological diagnosis has been performed in our patients due to the typical clinical and radiological findings. The distance from skin to the bone ranged from 4.1 cm to 8.3 cm (mean 6.5 cm, SD 1.8 cm). The diameter of OO ranged from 6 to 15 mm (mean 10 ± 2.6 mm): size greater than 15 mm was considered as exclusion criteria.

As inclusion criteria, we selected patients with a minimum distance of the bone lesion from the skin over 4 cm to prevent the risk of cutaneous and thermal lesions. Patients data is described in [Table 1](#T1){ref-type="table"}.

All patients had mainly nocturnal pain with positive temporary response to NSAIDs. Plain radiography and computed tomography (CT) scan showed a central radiolucent nidus surrounded by reactive bone sclerosis.

The procedures were performed using CT (Somatom Plus 64, Siemens Medical Solutions, Forchheim, Germany) under general anesthesia.

To perform RFA we used the RITA system (RITA Medical Systems, Mountain View, California, USA) composed of a radiofrequency monopolar generator 150--200W (Rita 1500 X, AngioDynamics Incorporated) and a needle electrode 14G with nine expandable active hooks and five thermocouples (monopolar Rita Starburst XL). The needle electrode allows controlled release of nine metal hooks that represent the active part that transmits energy. The tines are deployed and retracted with a simple helical rotation of the hub. Thermocouples placed at the tips of five prongs of the nine-array needle-electrode enabled continuous real-time monitoring of the actual temperatures at the tips. When deployed, the tines function as antennae, expanding and concentrating the current density and predictably enlarging the lesion.

Before the proce-dure, prothrombin time and international normalized ratio values were checked. In addition, whole blood count, allergy and anesthesia status were evaluated. All patient received preoperative short-term antibiotic prophylaxis with Cefamezin 2 g.

A CT scan was performed to localize the lesion and identify the optimal entry point. Two adhesive grounding pads were placed on the patient. A sterile field was prepared with povidone-iodine (10%) solution. A 2.2-mm Kirschner wire was inserted into the center nidus and then advanced and anchored about an inch and a half deeply in the bone ([Fig. 1a](#F1){ref-type="fig"}). A 2 cm skin incision and release adjacent soft tissue were performed at the K-wire entry point in order to ease the insertion of a 5 mm cannulated drill with the K-wire as a guide ([Fig. 1b](#F1){ref-type="fig"}). Once verified the position of the cannulated drill on the k-wire and the contact with the bone, a 5-mm diameter hole was drilled through the nidus using an electrical orthopedic drill under CT-guidance to create an optimal cavity to receive the multi-tined expandable electrode ([Fig. 1c](#F1){ref-type="fig"}). After the removal of cannulated drill and k-wire, the dispersive pads were connected to the generator to close the circuit and disperse the heat. The multi-tined expandable electrode was placed in its closed configuration at the center of the previously drilled hole ([Fig. 1d](#F1){ref-type="fig"}). Once connected to the radiofrequency generator, the electrode tines were deployed for about 1--1.5 cm to deliver energy to a wide area of bone lesion ([Fig. 1e](#F1){ref-type="fig"}).

![**a)**A 2.2-mm Kirschner wire inserted into the center nidus; **b)**Insertion of a 5-mm cannulated drill using the K-wire as a guide; **c)**Drilling of the cortical bone over the nidus; **d)**Insertion of the multi-tined expandable electrode in its closed configuration into the lesion; **e)**RF ablation of the lesion using the multi-tined expandable electrode in its open configuration](ACTA-88-31-g001){#F1}

A CT scan was obtained to verify the optimal placement of the electrodes. Afterwards, thermal ablation was performed with a target temperature of 90°C for 4--6 minutes. A laptop computer was used to graphically display, in real time, the curves of the temperatures at the tips, the power of the generator, and the impedance of the tissues over time. Once a rise in impedance was achieved and the thermal ablation ended, a final CT scan was performed.

We evaluated the clinical and perioperative course using medical records and patient labels. We analyzed preoperative, intraoperative and postoperative CT scans. Clinical evaluation was performed using a pain visual analogue scale (VAS) from 0 (no pain) to 10 (unbearable pain), considering a pain between 7 and 10 as severe, between 5 and 6 as moderate, and between 0 and 4 as slight. Pain was assessed preoperatively, 2 weeks postoperatively and at the time of the last follow-up. Complications were classified into major and minor according to the recommendations of the Society of Interventional Radiology ([@ref17]-[@ref18]). We defined recurrence as the persistence or return of symptoms after a remission.

Results were evaluated in terms of pain reduction or absence of pain. The difference between pre and postoperative pain was evaluated with paired T-test. Significance was set at a *P value* less than or equal to *0.05.*

###### 

Clinical data

  Patient                                 Age (yrs)   Gender   Side      Location    Size (mm)   Duration of pain (mo)   FU[\*](#t1f1){ref-type="table-fn"} (mo)
  --------------------------------------- ----------- -------- --------- ----------- ----------- ----------------------- -----------------------------------------
  1                                       15          M        Right     Femur       11          12                      74
  2                                       18          M        Right     Femur       9           7                       80
  3                                       16          F        Right     Tibia       6           9                       86
  4                                       22          M        Left      Tibia       8           6                       90
  5                                       19          F        Right     Femur       11          8                       75
  6                                       14          F        Left      Femur       9           9                       96
  7                                       18          M        Left      Femur       7           11                      94
  8                                       22          M        Left      Tibia       13          20                      90
  9                                       26          M        Left      Tibia       12          9                       88
  10                                      24          M        Left      Femur       7           24                      80
  11                                      20          F        Left      Femur       10          15                      73
  12                                      22          M        Right     Femur       11          16                      81
  13                                      18          M        Right     Tibia       8           12                      78
  14                                      17          M        Left      Femur       14          20                      94
  15                                      18          F        Left      Femur       15          14                      79
  16                                      20          F        Left      Tibia       12          8                       91
  Minimum                                 14          M:10     Left:10   Femur: 10   6           6                       73
  Maximum                                 26          F:6      Right:6   Tibia: 6    15          24                      96
  Average                                 19.3                                       10.2        12.5                    84.3
  SD [\*\*](#t1f2){ref-type="table-fn"}   3.3                                        2.6         5.3                     7.7

FU: follow up;

SD: standard deviation

Results {#sec1-4}
=======

All patients were available with an average follow-up of 84.3 ± 7.7 months (range 73--96 months). The results are described in [Table 2](#T2){ref-type="table"}.

The procedure was technically feasible in all patients. The mean operative time from induction of anesthesia was 65.5 ± 11.5 minutes (range 48--90 minutes). The clinical results according to VAS are summarized in [Table 2](#T2){ref-type="table"}: VAS pain scores improved at all postoperative time points. Mean preoperative pain score was 7.4±1.1 (range 5--9), two weeks after the procedure mean pain score was 0.3 (range 0--1) with a mean change of 7.06 points (p\<0.0001). At the last follow-up all patients reported a VAS score of 0. The percentage of clinical success was 100%. We did not observe any recurrence. No major and minor complications were observed.

Discussion {#sec1-5}
==========

The satisfactory clinical results reported in our retrospective study confirm the efficacy of RFA in the treatment of OO, as widely reported in the international literature ([@ref12], [@ref13], [@ref19]). In our study, RFA using a MTEES was completed successfully in all patients. Furthermore, in all cases we achieved complete remission of symptoms, without any recurrence of pain at last follow-up.

Several studies on RFA have shown a high safety with a complication rate as low as 3% ([@ref12], [@ref13], [@ref15], [@ref20]-[@ref22]). RFA complications are mostly due to cutaneous and thermal burns in the zone of approach ([@ref23]-[@ref25]). In this regard, attention should be given in the presence of superficial OOs, in which the distance between the skin and the bone is minimal, to avoid the risk of creating burns from thermal necrosis ([@ref24], [@ref26]-[@ref29]). Some authors also recommend using extra care when treating OOs located less than 10 mm from nerve or vascular structures ([@ref25], [@ref30]). In our study, there were no major or minor complications in intra and postoperative phases. Due to the device design, we choose to select patients in which the minimum distance of the bone lesion from the skin was over 4 cm to prevent the risk of cutaneous and thermal burns and allow an appropriate expansion of the hooks.

None of our patients had a histological diagnosis. The main disadvantage of percutaneous RFA is indeed the inability to get histological confirmation: the biopsy material is often poor in quality and quantity. Many authors argue that the histological diagnosis of OO before RFA is not needed due to the typical presentation ([@ref20]), however, others prefer to take a sample of tissue before treatment ([@ref31]). Furthermore, in case of treatment failure or relapse a histopathological confirmation may be needed ([@ref31]).

###### 

Procedure data and clinical results

  Patient                                Procedure time (min)   Bone-skin distance (mm)   Major complication   Minor complication   VAS[\*](#t2f1){ref-type="table-fn"} preop   VAS[\*](#t2f1){ref-type="table-fn"} 14 days postop   VAS[\*](#t2f1){ref-type="table-fn"} FU   Recurrence   F U[\*\*](#t2f2){ref-type="table-fn"} (mo)
  -------------------------------------- ---------------------- ------------------------- -------------------- -------------------- ------------------------------------------- ---------------------------------------------------- ---------------------------------------- ------------ --------------------------------------------
  1                                      65                     80                        None                 None                 7                                           0                                                    0                                        No           74
  2                                      48                     71                        None                 None                 8                                           1                                                    0                                        No           80
  3                                      62                     42                        None                 None                 7                                           0                                                    0                                        No           86
  4                                      55                     45                        None                 None                 9                                           1                                                    0                                        No           90
  5                                      70                     80                        None                 None                 7                                           1                                                    0                                        No           75
  6                                      65                     78                        None                 None                 6                                           0                                                    0                                        No           96
  7                                      72                     81                        None                 None                 8                                           0                                                    0                                        No           94
  8                                      80                     34                        None                 None                 6                                           0                                                    0                                        No           90
  9                                      70                     41                        None                 None                 5                                           0                                                    0                                        No           88
  10                                     80                     72                        None                 None                 8                                           0                                                    0                                        No           80
  11                                     50                     78                        None                 None                 8                                           1                                                    0                                        No           73
  12                                     55                     83                        None                 None                 7                                           0                                                    0                                        No           81
  13                                     68                     58                        None                 None                 7                                           0                                                    0                                        No           78
  14                                     90                     68                        None                 None                 8                                           1                                                    0                                        No           94
  15                                     60                     66                        None                 None                 9                                           0                                                    0                                        No           79
  16                                     58                     68                        None                 None                 8                                           0                                                    0                                        No           91
  Minimum                                48                     41                                                                  5                                           0                                                                                                          73
  Maximum                                90                     83                                                                  9                                           1                                                                                                          96
  Average                                65.5                   65                                                                  7.4                                         0.3                                                                                                        84.3
  SD[\*\*](#t2f2){ref-type="table-fn"}   11.5                   18                                                                  1.1                                         0.47                                                                                                       7.7

VAS: Visual analogue scale;

FU: follow up

Recurrence of pain after RFA is the result of incomplete tumor ablation ([@ref32]). Some authors reported a recurrence rate variable from 0 to 35% ([@ref14]-[@ref16], [@ref28], [@ref33]). Kjar and co-workers reported that the recurrence rate is significantly higher in OOs with a diameter greater than 10 mm ([@ref16]). In lesions greater than 10 mm reposition of the electrode needle and multiple ablations are recommended to reduce the risk of recurrence ([@ref14]-[@ref16]). In our study, we achieved clinical success without recurrence, even in those cases (7 patients) with a lesion larger than 10 mm. Because of our findings, we concur that the MTEES increases the volume of tissue heated, producing a larger ablation zone compared to a standard monopolar cannula.

Two protocols of RFA for the treatment of OO are usually reported in the literature: 4 minutes at 90°C ([@ref12], [@ref13], [@ref23], [@ref24]) or 6 minutes at 80°C ([@ref34]). In our study, we successfully applied a thermal ablation time of 4--6 minutes at 90°C. Moreover, real-time monitoring of the temperatures recorded on thermocouples, placed at the tips of the prongs of this system, and rise in impedance of the tissues over time proved to be effective in controlling the temperature reached during the procedure and in predicting a successful ablation ([@ref35]).

Conclusions {#sec1-6}
===========

RFA using a MTEES has proven to be effective, safe and reliable for the treatment of OOs. We did not report any recurrences despite the presence of a high number of patients with lesions greater than 10 mm. Expandable metal tines allowed to diffuse the RF current density in the target tissue thereby increasing the functional electrode surface area and the size of the necrosis. This device could be a viable alternative to the single needle electrode in the case of larger OOs, reducing the risk of recurrence. However, expandable needle systems are not suitable for OOs located superficially. Therefore, we recommend its use in lesions at least 4 cm deep, to allow an appropriate expansion of the tines and reduce the risk of skin burns. Further studies related to the use of this device in larger populations of patients are needed for proving its advantage over other currently available RFA systems.
